The primary efficacy endpoint was the non-inferiority of tirzepatide (10 mg or 15 mg) compared to insulin degludec in terms of the mean change from baseline in HbA1c at week 52
It works synergistically with the cytochrome P450 system, which is responsible for metabolizing drugs and other substances through "Phase I" (e.g., oxidation and reduction reactions), imparting certain polarity and reactivity
Inflammation resolution and matrix preservation Acute inflammation benefits: Initial inflammatory response (first days post-injury) clears debris, prevents infection, releases growth factors
Feb 2021;53(1):e13644
It was approved by the US Food and Drug Administration (FDA) as a 2-line drug for T2DM patients in 2005, and was marketed in China in 2009
4-Hydroxynonenal is involved in the signaling of cell proliferation and apoptosis, as well as regulating gene expression in different cell types (Yang et al., 2001